A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib

Acquired resistance to second generation BRAF inhibitors (BRAFis), like vemurafenib is limiting the benefits of long term targeted therapy for patients with malignant melanomas that harbor BRAF V600 mutations. Since many resistance mechanisms have been described, most of them causing a hyperactivati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinnberg, Tobias, Makino, Elena, Krueger, Marcel A., Velic, Ana, Macek, Boris, Rothbauer, Ulrich, Groll, Nicola, Pötz, Oliver, Czemmel, Stefan, Niessner, Heike, Meier, Friedegund, Ikenberg, Kristian, Garbe, Claus, Schittek, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919613/
https://www.ncbi.nlm.nih.gov/pubmed/27428425
http://dx.doi.org/10.1016/j.ebiom.2016.04.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919613/
https://www.ncbi.nlm.nih.gov/pubmed/27428425
http://dx.doi.org/10.1016/j.ebiom.2016.04.037

Ejemplares similares